21 Sep 2006 -
Ferro Pfanstiehl Laboratories, Inc., part of the Organic Specialties Group of Ferro Corporation, has commissioned a new validated cGMP supercritical fluid-based particle engineering pilot facility. The facility shall bring additional expertise in particle sizing, purification and formulation to fee-for-service pharmaceutical and biopharmaceutical customers. It shall provide ICH Q7A-compliant small-scale manufacturing of drug particles and compounds for use in Phase I and II clinical trials and feasibility studies of engineered particles for any desired drug delivery application.
Ferro Corporation's patented supercritical fluid (SCF) technologies utilize low-cost carbon dioxide to produce nano- and micro-particles with a narrow size distribution and consistent morphology. The particles manufactured using these technologies can be used in controlled release, taste masking, respiratory, transdermal and injectable drug delivery applications. According to the compnay, manufacturing benefits include reduced operating costs, near elimination of waste streams, easy recycling of organic solvents, and reduced cycle time.
Additional information
Ferro Corporation Cleveland, OH, United States of America
Top
Contact
Print version
PDF version
Send article
RSS feed